Difference between revisions of "Gene fusion"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) (+examples) |
Jensflorian (talk | contribs) (+cat) |
||
Line 23: | Line 23: | ||
* NAB2-STAT6 fusion in [[Solitary fibrous tumour]]. | * NAB2-STAT6 fusion in [[Solitary fibrous tumour]]. | ||
* RELA fusion in supratentorial [[ependymoma]] (up to 70% in children). | * RELA fusion in supratentorial [[ependymoma]] (up to 70% in children). | ||
==See also== | |||
*[[Molecular pathology]]. | |||
*[[Oncogene]]. | |||
[[Category:Molecular pathology]] |
Latest revision as of 08:23, 4 October 2018
Gene fusion is a common event in cancer and a re-occuring theme in molecular pathology. It is hybrid of two coding or regulatory DNA sequences.
General
Caused by genomic rearrangements such as:
- translocation.
- deletion.
- duplication.
- inversion.
First fusion was described as BCR-ABL1 fusion in CML. Subsequently Imatinib was the first inhibitor targeting CML with BCR-ABL1 fusion.
Methodology
Gene fusions can be detected by:
- RT-PCR (fusion partners need to be known).
- FISH.
- RNA-Sequencing.
- Whole Genome sequencing (WGS) (Comprehensive and unbiased, but short read length).
- Immunohistochemistry (not suitable/available for all fusions).
Examples
Common fusion in Neuropathology:
- KIAA1549-BRAF fusion in pilocytic astrocytoma (up to 70%).
- NAB2-STAT6 fusion in Solitary fibrous tumour.
- RELA fusion in supratentorial ependymoma (up to 70% in children).